CRINETICS PHARMACEUTICALS INC (CRNX) — insider trading
Health Care · NASDAQ
CRINETICS PHARMACEUTICALS INC (CRNX) has 40 reported SEC Form 4 insider transactions in our data, including 6 open-market sales among the most recent 40 (latest 2026-07-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Vivaldi Coelho Rogerio | Director | Open-market sale | 3,000 | $40.00 | $120.0K | Form 4 |
| 2026-06-18 | Okey Stephanie | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Okey Stephanie | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-18 | WIERENGA WENDELL | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | WIERENGA WENDELL | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Bedrosian Camille L | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Bedrosian Camille L | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Vivaldi Coelho Rogerio | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Vivaldi Coelho Rogerio | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Nichols Weston | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Nichols Weston | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Fust Matthew K | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Fust Matthew K | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Deardorf Caren | Director | Grant / award / vesting (derivative) | 9,730 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Deardorf Caren | Director | Grant / award / vesting | 5,925 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Okey Stephanie | Director | Open-market sale | 608 | $36.22 | $22.0K | Form 4 |
| 2026-06-17 | Okey Stephanie | Director | Open-market sale | 6,292 | $35.62 | $224.1K | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 111,100 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 80,000 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 222,200 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 222,200 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 80,000 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 222,200 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Struthers Richard Scott | Director, Officer (President & CEO) | Bona fide gift | 222,200 | $0.00 | $0 | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Option exercise / conversion (derivative) | 19,336 | $0.00 | $0 | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Option exercise / conversion (derivative) | 9,624 | $0.00 | $0 | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Option exercise / conversion (derivative) | 49,474 | $0.00 | $0 | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Open-market sale | 85,163 | $40.10 | $3.42M | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Option exercise / conversion | 19,336 | $19.64 | $379.8K | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Option exercise / conversion | 9,624 | $20.02 | $192.7K | Form 4 |
| 2026-04-08 | Knight Jeff E. | Officer (Chief Dev. & Operating Officer) | Option exercise / conversion | 49,474 | $23.98 | $1.19M | Form 4 |
| 2026-03-16 | Knight Jeff E. | Officer (Chief Operating Officer) | Open-market sale | 3,961 | $37.77 | $149.6K | Form 4 |
| 2026-03-16 | Knight Jeff E. | Officer (Chief Operating Officer) | Open-market sale | 5,950 | $37.11 | $220.8K | Form 4 |
Ask the chat about CRNX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CRINETICS PHARMACEUTICALS INC (CRNX).
Last updated 2026-07-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.